What is ALS Phase 2 Study KNS-760704 CL201?
CATEGORY:
NCT00647296 is a 2 part, randomized, double-blind, safety and tolerability study evaluating the drug KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The drug KNS-760704 is now known as dexpramipexole. Other study ID includes: KNS-760704-CL201.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 2 Study KNS-760704 CL201?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Amyotrophic lateral sclerosis | 4 | 2 | |
| Participate in clinical trial | 2 | 1 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Dry mouth | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 0 | |
| Mild | 1 | |
| None | 2 |
Member evaluations
y
Ya Mon
evaluated on Oct 24, 2009
- Perceived effectiveness for Participate in clinical trial: Major
- Side effects: None
Learn more about our community’s experience with ALS Phase 2 Study KNS-760704 CL201
What are people saying about ALS Phase 2 Study KNS-760704 CL201?
6
6
members have reported taking ALS Phase 2 Study KNS-760704 CL201
Join the conversation and connect with people who have taken ALS Phase 2 Study KNS-760704 CL201
Last updated: